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BackgroundzzWe describe herein the application of whole exome sequencing (WES) for the 
molecular genetic diagnosis of a large Korean family with dominantly inherited myopathy.
Case ReportzzThe affected individuals presented with slowly progressive proximal weak-
ness and ankle contracture. They were initially diagnosed with limb-girdle muscular dystro-
phy (LGMD) based on clinical and pathologic features. However, WES and subsequent capil-
lary sequencing identified a pathogenic splicing-site mutation (c.1056+1G>A) in COL6A1, 
which was previously reported to be an underlying cause of Bethlem myopathy. After identi-
fication of the genetic cause of the disease, careful neurologic examination revealed subtle 
contracture of the interphalangeal joint in the affected members, which is a characteristic 
sign of Bethlem myopathy. Therefore, we revised the original diagnosis from LGMD to Beth-
lem myopathy.
ConclusionszzThis is the first report of identification of COL6A1-mediated Bethlem myopathy 
in Korea, and indicates the utility of WES for the diagnosis of muscular dystrophy.
Key Wordszz Bethlem myopathy, collagen type VI alpha 1 (COL6A1),  
whole exome sequencing.
Molecular Genetic Diagnosis of a Bethlem Myopathy Family 
with an Autosomal-Dominant COL6A1 Mutation,  
as Evidenced by Exome Sequencing
INTRODUCTION
Muscular dystrophy is a clinically and genetically heterogeneous inherited disorder char-
acterized by progressive muscle weakness and wasting. A step-by-step approach with as-
sessment of medical history, clinical examination, laboratory evaluation, muscle patholo-
gy, muscle immunoanalysis, and mutational analysis is typically used for the diagnosis of 
muscular dystrophy.1,2 However, this serial approach often fails to identify causative mu-
tations due to high phenotypic and pathologic variability, small pedigrees, and the limited 
power of traditional linkage analyses.3 Recent advances in next-generation sequencing 
has made it possible to selectively sequence only the protein-coding exons of the genome, 
a process termed ‘whole exome sequencing’ (WES). The application of WES not only 
saves time but is also cost-effective for the identification of causative genes in Mendelian 
diseases.4 Therefore, WES is being increasingly adopted for the identification of causative 
genes in muscular dystrophy research.5-8
Herein we report a mutation in the gene encoding collagen type VI α1 (COL6A1) in a 
large Korean family with autosomal-dominant Bethlem myopathy that was detected us-
ing WES.
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CASE REPORT
Eighteen members of a large Korean family with domi-
nantly inherited myopathy (7 affected and 11 unaffected) 
were enrolled (Fig. 1A). Written informed consent to par-
ticipate was obtained from all participants and from the 
parents of participants younger than 18 years, according to 
a protocol approved by the Institutional Review Board for 
Ewha Womans University Mokdong Hospital, Seoul, Korea.
Patients
The proband, a 38-year-old woman (III-4), presented with 
progressive proximal weakness and ankle contractures (Sup-
plementary Table 1 in the online-only Data Supplementary). 
Her initial development after birth was reportedly normal, 
but she did not begin walking until she was 16 months old. 
She recalled that she had always been weaker than her peers. 
Her motor function remained relatively stable until her mid-
20s. However, she experienced slowly progressive muscle 
weakness after the delivery of her first child at an age of 27 
years. Her neck flexors [Medical Research Council (MRC) 
grade 3] appeared to be more damaged than her neck ex-
tensor (MRC grade 4+). The proximal muscles of her upper 
and lower limbs were more severely involved than the distal 
muscles, and her ankle joints were affected by contracture. 
In addition, she appeared to exhibit mild facial weakness 
and absent tendon reflexes in the upper and lower limbs. 
However, sensory examination revealed no abnormalities. 
Laboratory studies revealed a serum creatine kinase level of 
66 IU/L (normal, <135 IU/L), and her vital capacity was 
3,120 mL. Electrocardiography and echocardiography find-
ings were normal. Nerve conduction studies and needle 
electromyography revealed active generalized myopathy. A 
muscle biopsy sample obtained from the left biceps brachii 
revealed nonspecific muscular dystrophic changes. Hema-
toxylin and eosin staining revealed variation in muscle fiber 
size (Fig. 2A), and modified Gomori trichrome staining re-
vealed a few ragged red fibers (Fig. 2B). Architectural changes 
of disorganized intermyofibrillar networks, such as lobulated 
fibers, were accentuated in staining with nicotinamide ade-
nine dinucleotide tetrazolium reductase (Fig. 2C). In addi-
tion, adenosine triphosphatase (pH 9.4) staining demonstrat-
1
I
II
III
IV
1
1
1
3
3
3
2
2
2
2
4
4
4
5
5
5
6
6
6
7
7
7
8
8
9
9
10
10
11
11 12 13 14
G/GG/GG/GG/G
Wild allele Mutated allele (c.1056+1G>A)
Exon 14 Intron Exon 14 Intron
G/G G/G G/G
G/G
G/G G/G G/GG/AG/AG/A
G/A G/A
G/AG/A
*
* * *
A  
B  
Fig. 1. A: Pedigree of an autosomal-dominant Bethlem myopathy family. Asterisks (*) indicate individuals whose DNA was used for exome se-
quencing. Genotypes of COL6A1 (c.1056+1G>A) are indicated under each subject (arrow, proband; square, male; circle, female; filled, affected; not 
filled, unaffected; diagonal bar across symbol, deceased). B: Sequencing chromatograms of the c.1056+1G>A splicing-site mutation in COL6A1. Ar-
row indicates the polymorphic site. The COL6A1 mutations detected by exome sequencing were confirmed by capillary sequencing. The heterozy-
gous c.1056+1G>A mutation was completely cosegregated with the affected individuals within this family, and was not found in a sample of 200 
healthy controls.
www.thejcn.com  185
Park HJ et al. JCN
ed a 69% predominance of type I fibers (Fig. 2D). Electron 
microscopy revealed many mitochondria, and immunohis-
tochemical analyses of the muscle specimens revealed nor-
mal staining patterns for the C-terminal of dystrophin, rod 
domain of dystrophin, N-terminal of dystrophin, dysferlin, 
α-sarcoglycan, β-sarcoglycan, γ-sarcoglycan, δ-sarcoglycan, 
α-dystroglycan, and caveolin.
The other affected members of the family had similar clin-
ical presentations (Supplementary Table 1 in the online-on-
ly Data Supplementary). They experienced very slow pro-
gressive muscle weakness and lived without significant 
disability until old age. Subject II-2 required aid for ambu-
lation after the age of 50 years, while subject II-3 (61 years 
old) was able to walk independently. The ankle joints were 
affected by contracture in all seven affected patients, while 
the elbow joints were involved only in subject II-2. Based on 
the clinical and pathologic features, the family was initially 
diagnosed with autosomal-dominant limb-girdle muscular 
dystrophy.
After identification of the causative gene, all affected mem-
bers underwent a second neurologic examination. This iden-
tified contracture of the interphalangeal joint–which is a 
characteristic sign of Bethlem myopathy–in five family mem-
bers (II-2, II-3, III-4, III-6, and IV-7). These contractures 
were very subtle and were not found on routine neurologic 
examination; they were only apparent when the wrist and fin-
gers were extended passively.
Genetic analysis
Whole exome sequencing was performed for five members 
of the family, including four affected members (II-3, III-4, 
IV-7, and IV-8) and one unaffected member (IV-6) to iden-
tify the genetic causes of the disease, following the method 
described by Choi et al.9 The exome sequencing data are 
summarized in Supplementary Table 2 (in the online-only 
Data Supplementary). The mean total sequencing yield was 
9.3 Gbp/sample, and the coverage rate of the targeted exon 
regions (≥10×) was 93.56%. The average read depth of the 
target regions was 69.3 reads, and the average number of 
observed variants per sample was 92,174 SNPs and 9,321 in-
dels. By comparing the exome data between 4 affected and 
1 unaffected family members, we found that 15 functionally 
significant cosegregated variants (Supplementary Table 3 in 
the online-only Data Supplementary). Subsequent capillary 
Fig. 2. Histopathologic observations of biceps brachii muscle samples taken from the proband (III-4). A: Hematoxylin and eosin staining revealed 
variations in muscle fiber size and some fibers with internal nuclei (×200). B: Modified Gomori trichrome staining revealed a few ragged red fibers 
(×200). C: Staining with nicotinamide adenine dinucleotide tetrazolium reductase revealed architectural changes of disorganized intermyofibrillar 
networks, such as lobulated fibers (×400). D: Adenosine triphosphatase (pH 9.4) staining demonstrated a 69% predominance of type I fibers (×100).
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sequencing analysis of control samples and other family 
members who were not included in the exome sequencing 
excluded most variants as the underlying cause of myopathy. 
However, a c.1056+1G>A splicing-site mutation in COL6A1 
completely cosegregated with affected status within the fam-
ily (Fig. 1B), and was not found in 200 healthy controls. 
This mutation has been reported to be the underlying cause 
of Bethlem myopathy.10-13 Thus, we determined that the 
c.1056+1G>A mutation in COL6A1 was the underlying 
cause of the disease in this family.
DISCUSSION
Whole exome sequencing of five members from a single fam-
ily identified a splice donor site mutation at c.1056+1G>A 
of COL6A1. This mutation causes the formation of abnormal 
collagen VI protein by skipping of exon 14 and consequent 
in-frame deletion of amino acids from the triple helical do-
main of the α1 chain.12
Bethlem myopathy is a dominantly inherited myopathy 
caused by mutations in one of three genes encoding colla-
gen type VI alpha (COL6A1, COL6A2, and COL6A3).14 The 
phenotype is characterized by slowly progressive proximal 
weakness and multiple contractures. Prominent contracture 
in the early stages of the disease is one of the most important 
clinical features in Bethlem myopathy, Emery-Dreifuss mus-
cular dystrophy, and Ullrich congenital muscular dystrophy. 
Among these conditions, Bethlem myopathy demonstrates 
the most benign clinical course and mildest contractures.
Bethlem myopathy is often difficult to diagnose and its 
frequency may be underestimated for several reasons. First, 
mild contractures often lead to confusion in the diagnosis.15,16 
In the present family, even though ankle contracture was 
initially detected, this is a common nonspecific finding in 
many other neuromuscular diseases. Contracture of the in-
terphalangeal joint is a hallmark of Bethlem myopathy, but 
is often so subtle that it goes unrecognized. Second, muscle 
biopsy is not typically used for confirmatory diagnosis of 
Bethlem myopathy due to nonspecific myopathic changes 
and lack of detected abnormalities of collagen VI, even in 
immunohistochemical analyses. Both Ullrich congenital 
muscular dystrophy and Bethlem myopathy are collagen-IV-
related myopathies. Immunohistochemistry in Ullrich con-
genital muscular dystrophy exhibits complete absence or 
unequivocal reduction of collagen VI compared to normal; it 
can thus be used for diagnostic purposes. However, in Beth-
lem myopathy, immunostaining of muscle biopsy with vari-
ous collagen VI antibodies is usually normal.14 Third, identi-
fication of the causative genes by general sequencing is costly 
and time-consuming because it is necessary to screen all 107 
exons in all 3 genes for molecular genetic diagnosis. For 
these reasons, careful clinical assessment and cost-effective, 
time-saving strategies for genetic analysis are important for 
the diagnosis of Bethlem myopathy.
Whole exome sequencing is a well-justified strategy for 
discovering the causative genes of muscular dystrophy. WES 
is based on next-generation sequencing, which reduces the 
cost and time relative to Sanger sequencing.17 In addition, 
WES focuses only on protein-coding regions, but it is still 
an effective diagnostic tool because more than 90% of the 
pathogenic mutations for Mendelian disorders are found in 
exons.4
In conclusion, we identified a COL6A1 mutation in a Ko-
rean family with Bethlem myopathy; this is the first such re-
port in Korea. Even though the causative mutation identi-
fied in the present study has been reported previously, this 
work underscores the usefulness of WES for the diagnosis 
of muscular dystrophy.
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